Amylyx Pharmaceuticals, Inc. 10-K filing
Filed 2026-03-03 · Report date 2025-12-31 · 2025 FY
Filing metadata
- Accession number
- 0001193125-26-086645
- Form type
- 10-K
- CIK
- 0001658551
- Primary document
- https://www.sec.gov/Archives/edgar/data/1658551/000119312526086645/amlx-20251231.htm
Extracted primary information
This filing includes deterministic financial metrics extracted from public filing data for Amylyx Pharmaceuticals, Inc..
Reported financial metrics
| Metric | Current | Prior | Change |
|---|---|---|---|
| Revenue | $0 | - | - |
| Cost Of Revenue | $0 | - | - |
| Operating Income | $-153.3M | - | - |
| Net Income | $-144.7M | - | - |
| Eps Basic | -1.53 | - | - |
| Eps Diluted | -1.53 | - | - |
| Cash And Equivalents | $226.7M | - | - |
| Total Assets | $332.6M | - | - |
| Total Liabilities | $27.4M | - | - |
| Shareholders Equity | $305.3M | - | - |
| Operating Cash Flow | $-123.3M | - | - |
| Capital Expenditures | $138,000 | - | - |